Is Bristol-Myers Squibb Stock Mounting a Sustained Recovery?

After an extended period of decline, Bristol-Myers Squibb shares are showing signs of a potential turnaround. A combination of robust quarterly earnings, a favorable regulatory development, and renewed confidence from market analysts is injecting fresh momentum into the equity. The critical question for investors is whether this represents the beginning of a durable recovery or merely a temporary rebound following the significant drop witnessed since the start of the year.

As market participants focus heavily on impending patent expirations for key drugs like Eliquis and Opdivo, Bristol-Myers Squibb is aggressively advancing its strategic transformation. The company’s growth portfolio delivered an impressive 18% increase in the third quarter, effectively counterbalancing declines from Read more...